Dec 19 0 NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate By Cain | Featured
Jan 16 0 ZymoChem Closes $21M Series A Round Led by Breakout Ventures with Investments from lululemon and Toyota Ventures By Cain | Featured
Oct 19 0 Debut Set to Revolutionize the Fragrance Industry with Proprietary Advanced Biomanufacturing, Closes More Than $40 Million in Additional Series B Funding By Cain | Featured
Recent Comments